Financing ·
Repligen issues $1.0 billion of 0.25% convertible notes due 2031 in exchange and cash transactions
RGENRepligen Corp
On November 6, 2026, Repligen Corporation issued $1.0 billion aggregate principal amount of its 0.25% Convertible Senior Notes due 2031 under a new Indenture with U.S. Bank Trust Company as trustee. Approximately $541.4 million in new notes was exchanged for $456.8 million of the company's existing 1.00% Convertible Senior Notes due 2028, which were canceled, while approximately $458.6 million in new notes was issued for cash. Following these transactions, about $143.2 million of the original 2028 notes remains outstanding with unchanged terms. The new senior unsecured obligations pay interest semi-annually at 0.25% per annum and mature on November 1, 2031. The initial conversion rate is 4.4176 shares per $1,000 principal amount, representing a conversion price of approximately $226.37 per share. Repligen Corporation operates in the biotechnology industry, providing equipment and services for the development and manufacture of biological products.